Molinalogo

Measure

2021

2022

Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

54.44%

60.29%

64.52%

Annual Dental Visits (ADV)

42.68%

50.02%

53.67%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

34.63%

44.39%

46.09%

Appropriate Testing for Pharyngitis (CWP)

84.99%

76.51%

74.02%

Appropriate Treatment for Upper Respiratory Infection (URI)

82.13%

83.82%

92.46%

Asthma Medication Ratio (AMR) Total

70.14%

66.86%

68.21%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB)

46.65%

41.97%

58.74%

Breast Cancer Screening (BCS)

44.67%

43.31%

53.96%

Cervical Cancer Screening (CCS)

70.80%

47.19%

60.83%

Childhood Immunization Status (CIS) Combination #10

35.28%

32.12%

39.42%

Chlamydia Screening in Women (CHL) Total

57.68%

57.16%

60.24%

Comprehensive Diabetes Care (CDC) BP Control < 140/90

55.23%

55.96%

65.21%

Comprehensive Diabetes Care (CDC) HbA1c Control <8.0%

35.28%

43.80%

52.80%

Comprehensive Diabetes Care (CDC) Eye Exam

45.99%

43.55%

54.74%

Controlling High Blood Pressure (CBP)

49.88%

47.20%

63.50%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

81.58%

81.82%

81.21%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

29.30%

14.78%

16.16%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

33.00%

31.05%

45.35%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

30.73%

31.90%

42.75%

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total

38.30%

36.64%

37.86%

Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase

51.07%

49.08%

55.40%

Immunizations for Adolescents (IMA) Combination #2

34.06%

33.31%

39.16%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

24.29%

21.05%

16.57%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Total

34.81%

33.33%

39.29%

Pharmacotherapy for Opioid Use Disorder (POD) Total

27.38%

19.04%

33.15%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

49.62%

76.52%

74.76%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

63.05%

85.22%

87.83%

Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years

108.48%

97.27%

≤ 94.44%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

78.83%

82.48%

87.83%

Prenatal and Postpartum Care (PPC) Postpartum Care

72.75%

71.29%

80.00%

Prenatal Immunization Status (PRS) Combination Rate

NR

NR

27.32%

Risk of Continued Opioid Use (COU) 31-Day Total

5.04%

3.64%

≤ 2.35%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

64.77%

80.13%

82.29%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

64.30%

70.26%

73.75%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

55.18%

66.35%

68.32%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

63.52%

66.25%

70.00%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

65.35%

65.91%

65.63%

Use of Imaging Studies for Low Back Pain (LBP)

67.76%

64.32%

76.82%

Use of Opioids at High Dosage (HDO)

0.69%

0.90%

≤ 2.65%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

2.10%

2.36%

≤ 0.90%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

50.61%

68.37%

82.73%